Susan Lindquist - Johnson Johnson Independent Director
| JNJ Stock | USD 149.56 0.44 0.30% |
Director
Dr. Susan L. Lindquist, Ph.D., is an Independent Director of Johnson And Johnson. She joined the Board of Directors in 2004 and is Chairman of the Science, Technology Sustainability Committee and a member of the Regulatory, Compliance Government Affairs Committee. She is a member of the Whitehead Institute, a nonprofit, independent research and educational institution, a Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. Dr. Lindquist served as Director of the Whitehead Institute from 2001 to 2004. Previously she was affiliated with the University of Chicago where she was the Albert D. Lasker Professor of Medical Sciences in the Department of Molecular Genetics and Cell Biology. Dr. Lindquist was elected to the American Academy of Arts and Sciences in 1996, the National Academy of Sciences in 1997, the American Philosophical Society in 2003 and the Institute of Medicine in 2006. She received the NovartisDrew Award for Biomedical Research in 2000, the Dickson Prize in Medicine in 2002, the Sigma Xi William Procter Prize for Academic Achievement in 2006, the Nevada Silver Medal for Scientific Achievement in 2007, the Genetics Society of America Medal and the Centennial Medal of the Harvard University Graduate School of Arts and Sciences in 2008. In 2010, she received the Mendel Medal from the Genetics Society, The Delbrck Medal from Bayer Schering, and the National Medal of Science . In 2012, Dr. Lindquist received the Wilson Medal in Cell Biology and in 2013 the Dart Prize in Biotechnology. She has served on the Scientific Advisory boards of many independent research institutes, associations and foundations, including the Massachusetts General Hospital, Brigham and Womens Hospital and the Institute fr Molekulare Biotechnology GmbH since 2004.
| Age | 65 |
| Tenure | 20 years |
| Address | One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.26 this year, although the value of Return On Assets will most likely fall to 0.14. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Floyd Bloom | Alkermes Plc | 80 | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| David Anstice | Alkermes Plc | 69 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Norah Barlow | Evotec SE ADR | N/A | |
| Hamish Stevens | Evotec SE ADR | N/A | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Duane Arsdale, Treasurer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Jasmina Brooks, President Webster | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Nadja West, Independent Director | ||
| Mark Larkins, Worldwide Secretary | ||
| Vanessa Broadhurst, Executive Vice President Global Corporate Affairs | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Tom Cavanaugh, Company Medicine | ||
| D Davis, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Ian Davis, Independent Director | ||
| Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
| Mark Weinberger, Independent Director | ||
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Executive CFO | ||
| Michael Bodner, Global Recovery | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Mary Beckerle, Independent Director | ||
| Darius Adamczyk, Independent Director | ||
| Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
| Scott Davis, Director | ||
| Hani Abouhalka, Company Digital | ||
| Ahmet Tezel, Group RD | ||
| Robert Decker, Controller Officer | ||
| Mathai Mammen, Executive Vice President Pharmaceuticals, R&D | ||
| Timothy Schmid, Executive MedTech | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | ||
| James Swanson, Executive Vice President, Chief Information Officer | ||
| Hubert Joly, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health | ||
| Jessica Moore, Vice Relations | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Celine Martin, Group CSS | ||
| Eugene Washington, Independent Director | ||
| Elizabeth Forminard, Executive Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Guy MD, Group EMEA | ||
| Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 | ||||
| Profit Margin | 0.47 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 366.7 B | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Institutions | 71.19 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 24.69 X | ||||
| Price To Book | 5.17 X |
Johnson Johnson Investors Sentiment
The influence of Johnson Johnson's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Johnson. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Johnson Johnson's public news can be used to forecast risks associated with an investment in Johnson. The trend in average sentiment can be used to explain how an investor holding Johnson can time the market purely based on public headlines and social activities around Johnson Johnson. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Johnson Johnson's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Johnson Johnson's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Johnson Johnson's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Johnson Johnson.
Johnson Johnson Implied Volatility | 21.69 |
Johnson Johnson's implied volatility exposes the market's sentiment of Johnson Johnson stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Johnson Johnson's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Johnson Johnson stock will not fluctuate a lot when Johnson Johnson's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.106 | Dividend Share 4.76 | Earnings Share 7.43 | Revenue Per Share 34.402 | Quarterly Revenue Growth (0.14) |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.